Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

LUND, Sweden, Aug. 2, 2021 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix®▼ (imlifidase) is, as of August 1, reimbursable and available for...

from PR Newswire: https://ift.tt/3yn77rh